Denmark-based Xellia Pharmaceuticals will invest $100 million in the expansion of its newly-purchased Raleigh, North Carolina manufacturing plant and create 40 new full-time jobs.
Xellia, who focuses on important anti-infective treatments against serious infections, acquired Fresenius Kabi’s dedicated lyophilized vial manufacturing facility in Raleigh, North Carolina in July. Located close to Research Triangle Park, the facility is Xellia’s first manufacturing operation in the U.S. and significantly expands the company’s injectable pharmaceutical products manufacturing capacity.
A business incentives grant will allow Xellia a 50 percent "pgrant" based on paid property taxes to the City of Raleigh over five years once a "minimal" investment of $100 million investment is made. In addition to creating 40 new jobs, Xellia intends to retain all ~80 staff currently employed at the site.
Read the WRAL TechWire press release